Phase 3 N=473 Treatment of Multiple Attacks of Acute Migraine (0462-025)
Migraine Headache
Primary: Pain Relief at 2 Hours During the First Migraine Attack Period — 246; 30; 74; 52 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=31 Treatment of Acute Migraine Headache in Children
Migrainous Headache
Primary: The Number of Subjects With a Numeric Rating Scale Score (NRS) of Zero at Two Hours. — 5; 12 participants — p=0.03
Phase 4 N=220 Corticosteroids for Acute Migraine in the Emergency Department
Migraine
Primary: Headache Days as Self-reported by Participants — 3.0; 3.3 days
Phase 3 N=1,594 Maximizing Outcomes in Treating Acute Migraine
Migraine
Primary: Percentage of Subjects Reporting Headache Pain Freedom — 85; 14 Participants — p=<0.001
Phase 3 N=902 Phase 3 Study of MAP0004 in Adult Migraineurs
Migraine Disorders
Primary: Number of Subjects With Pain Relief at 2 Hours From Time of First Dose — 136; 231 participants
Phase 2 N=676 MK3207 for Treatment of Acute Migraines (3207-005)
Migraine
Primary: Pain Freedom (PF) — 13; 4; 5; 16 Participants — p=<0.001
Phase 2 N=75 Staccato Prochlorperazine in Migraine (in Clinic)
Migraine Headache, With or Without Aura
Primary: Headache Pain Relief at 2 hr Post-dose by 2-point Definition — 6; 11; 13 Participants
Phase 3 N=207 Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081)
Migraine
Primary: Number of Participants Who Are Pain Free at 2 Hours Post-Dose — 61; 27 Participants
Phase 4 N=208 Diphenhydramine for Acute Migraine
Migraine
Primary: Number of Participants With Sustained Headache Relief Assessed by Self-evaluation — 40; 38 Participants
Phase 3 N=2,231 Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
Acute Migraine
Primary: Percentage of Participants Who Are Headache Pain Free — 28.2; 32.2; 15.3 percentage of participants — p=<0.001
Phase 4 N=50 Trial of Comprehensive Migraine Intervention
Migraine
Primary: Migraine Functional Impairment as Measured by Score on the Headache Impact Test 6 (HIT6) Scale — 59; 56 units on a scale
Phase 3 N=1,473 MK0462 in Treatment of Migraine With Recurrence (MK0462-022)
Migraine Headache
Primary: Pain Relief at 2 Hours After the Initial Dose of Test Drug — 285; 322; 106; 172 Participants
Phase 3 N=679 TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)
Migraine, Without Aura
Primary: Pain-Free at 2 Hours Post-dose and Sustained Pain-Free From 2-24 Hours Post-dose. — 25; 64; 20; 54 Participants — p=<0.001
Phase 3 N=194 A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)
Acute Migraine
Primary: Pain Relief (PR) — 102; 21; 100; 78 attacks — p=<0.001
Phase 3 N=349 Metoclopramide for Migraine: A Dose Finding Study
Migraine
Primary: Pain Intensity Score — 4.7; 4.9; 5.3 scores on a scale
Phase 3 N=933 MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)
Migraine Headache
Primary: Pain Relief at 2 Hours After Treatment — 223; 238; 18; 129 Participants
Phase 3 N=205 Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines
Migraine
Primary: Persistent Headache Pain Free at 24 Hours — 26; 19 Participants
Phase 3 N=302 Initiating Early Control of Migraine Pain and Associated Symptoms
Migraine
Primary: Percentage of Subjects Achieving Headache Pain Freedom at Hour 2 — 43; 22 Participants — p=0.002
Phase 3 N=1,466 Trial in Adult Subjects With Acute Migraines
Migraine, With or Without Aura
Primary: Percentage of Participants With Freedom From Pain at 2 Hours Post-dose — 21.2; 10.9 percentage of participants — p=< 0.0001
Phase 3 N=28 Greater Occipital Nerve Block With Bupivacaine for Acute Migraine
Migraine
Primary: Number of Participants Who Achieve Freedom From Headache — 4; 0 Participants
Phase 4 N=752 Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine
Pain, Migraine
Primary: Percent of Subjects Who Are Pain Free at 2 Hours. — 34.7; 44.9; 26.4 Percent of participants
Phase 2 N=21 A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine
Acute Migraine
Primary: Change in Migraine Headache Pain Score From Time of Dosing (0 Minutes) — 0; 0.2; -0.8; -0.2 score on a scale — p=0.9733
Phase 4 N=40 Ticagrelor Therapy for RefrACTORy Migraine Study
Migraine · Headache · Migraine Headache
Primary: Total Number of Responders — 17 Participants
Phase 2 N=366 Staccato Loxapine in Migraine (Out Patient)
Migraine Headache
Primary: Pain-Relief at 2 Hours Post-treatment — 56; 65; 66 Participants
Phase 3 N=1,380 Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)
Migraine
Primary: Number of Participants With Pain Freedom (PF) at 2 Hours Post-Dose — 56; 89; 101; 29 Participants — p=<0.001
Phase 4 N=232 Drug and Non-Drug Treatment Of Severe Migraine
Migraine Headache
Primary: Change in Number of Migraine Episodes Per 30 Days at Month 10. — -2.1; -2.1; -2.2; -3.3 Number of Migraine episodes — p=< .01
N/A N=568 Study of Two Digital Therapeutics for the Prevention of Episodic Migraine
Migraine · Episodic Migraine · Headache
Primary: Change in MMD (Monthly Migraine Days) — -3.04; -2.14 migraine days per month
Phase 3 N=1,268 Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)
Migraine Headache
Primary: Pain Relief at 2 Hours After Dose — 99; 258; 239; 64 Participants
Phase 2 N=84 CHOCOlate MeLatonin for AdolescenT MigrainE
Migraine
Primary: Change in Mean Visual Analog Scale (VAS) Score — -2.3; -2.7 cm
Phase 3 N=3,005 Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine
Migraine With or Without Aura
Primary: Percentage of Participants Headache Pain Free at 2 Hours Post Dose — 28.6; 31.4; 38.8; 21.3 percentage of participants — p=0.003